Cancer immunotherapy: harnessing the immune system to battle cancer

2015/08/31 by Yiping Yang · 1 citation
Medicine · Immunology and Microbiology · #CAR-T cell therapy research #Cancer Immunotherapy and Biomarkers #Immunotherapy and Immune Responses

paper · pdf · doi:10.1172/jci83871

openalex publication_date 2015/08/31 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01

Abstract

The recent clinical successes of immune checkpoint blockade and chimeric antigen receptor T cell therapies represent a turning point in cancer immunotherapy. These successes also underscore the importance of understanding basic tumor immunology for successful clinical translation in treating patients with cancer. The Reviews in this Review Series focus on current developments in cancer immunotherapy, highlight recent advances in our understanding of basic aspects of tumor immunology, and suggest how these insights can lead to the development of new immunotherapeutic strategies.

Citations

• Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages
• Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
• Neoantigens in cancer immunotherapy
• CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

Cited by

• Immune system [wikipedia]

Related

• Immunotherapy of cancer in 2012
• Cancer immunotherapy: The past, the present and the future
• Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma
• Harnessing the immune system and developing targeted vaccines: overall strategies of leveraging the body’s natural defense mechanisms to enhance cancer treatment
• The Landmark Series: Cancer Vaccines for Solid Tumors